Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma.
Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Smith R, Panozzo S, Alapat D, Tricot G, Shaughnessy J, Zhan F, Sawyer J, Siegel ER, Barlogie B, van Rhee F, Zangari M. Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma. Blood Adv. 2025 Feb 25; 9(4):950-953.